Glucagon-like peptide-1: Gastrointestinal function and possible mechanism of action

Danish Medical Bulletin

Volumn 48, Issue 1, 2001, Pages 19-28

  Wettergren, A ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-37] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

FOOD INTAKE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; HORMONE ACTION; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; INTESTINE ADAPTATION; INTESTINE MOTILITY; NONHUMAN; OBESITY; PANCREAS; PANCREAS SECRETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; STOMACH ACID SECRETION; STOMACH MOTILITY;

DIABETES MELLITUS; DIGESTIVE SYSTEM; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0035115950     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
2. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man
3. Secretion of the incretin hormones glucagon-like peptide-1 and the gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day
4. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effects on gastric acid secretion in man
5. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in man depends on an intact vagal innervation
6. The inhibitory effect of glucagon-like peptide-1(7-36) amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36) amide
7. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): Non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans
8. Glucagon-like peptide-1 (GLP-1) inhibits antral motility and gastro-pancreatic secretion by inhibiting central parasympathetic outflow
9. Effect of peptide YY on gastric, pancreatic, and biliary function in humans
10. Incomplete absorption of the carbohydrate in all-purpose wheat flour
11. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine ileum-jejunum. Characterization of the peptide
12. Exon duplication and divergence in the human preproglucagon gene
13. Hamster proglucagon contains the sequence of glucagon and two related peptides
14. Gut-hormone profile in coeliac disease
15. Gut hormones in acute diarrhoea
16. Gut hormone in tropical malabsorption
17. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides
18. Inhibition of gastric acid secretion in man by exogenous and endogenous pancreatic glucagon
19. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
20. Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig
21. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
22. Peripheral regulation of gastric secretion
23. Symposium: Restorative proctocolectomy with ileal reservoir
24. The effect of glucagon on gastric secretion in man
25. 2]glucagon-like peptide 2
26. Induction of intestinal epithelial proliferation by glucagon-like peptide-2
27. Pouchitis and gastric hyposecretion: Cause or effects?
28. Glucagon-like peptide-1 reduces postprandial glycemic excurisions in IDDM
29. Glucagone-like peptide-1 cells in the gastrointestinal tract and pancreas of the rat, pig and man
30. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat
31. Glucagon-like peptide-1 (7-36) amide and the glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute postprandial and 24-h secretion patterns
32. Meeting report from the international symposium on GLP-1
33. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin releasing polypeptide (GIP)
34. Interaction of glucagon-like peptide-1 (7-36) amide and cholecystokinin-8 in the endocrine and exocrine rat pancreas
35. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-1 but not by CCK-8
36. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans
37. Glucagon-like peptide-1 (7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition in dogs
38. Molecular forms of glucagon-like peptides in man
39. Is GLP-1 (9-36)amide an endogenous antagonist at the GLP-1 receptors?
40. Effect of monoclonal antibodies to enteroglucagon on ileal adaptation after proximal small bowel resection
41. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting βTC3-cells by enhancement of intracellular calcium mobilization
42. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin and glucagon interact with a common receptor in a somatostatin-secreting cell line
43. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
44. Glucagon-like peptide-1 is a physiologic regulator of food intake in humans
45. Distribution of the GLP-1 binding sites in the rat brain. Evidence that exendin 4 is a ligand of the brain GLP-1 binding sites
46. Cellular localization of proglucagon/glucagon-like peptide 1 messenger RNAs in the rat brain
47. Pancreatone, an inhibitor of the pancreatic secretion in extrats of ileal and colonic mucosa
48. Glucagon-like peptide-1 and the glucose-dependent insulin-releasing peptide plasma levels in response to nutrients
49. Galanin is a potent inhibitor glucagon-like peptide-1 secretion from rat ileum
50. Glycine-extended gastrin precursors
51. Enteroglucagon
52. Evidence that enteroglucagon (II) is identical with the c-terminal sequence (residues 33-69) of the glicentin
53. Glucagonlike peptide 1: A newly discovered gastrointestinal hormone
54. Proglucagon processing in the porcine and human pancreas
55. Effects of the intestinal inhibitory peptides on vagally induced secretion from the isolated perfused porcine pancreas
56. Transmitters in the control of gastrin and acid secretion in the pig stomach
57. Nervous control of pancreatic exocrine secretion in pigs
58. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human obesity
59. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio
60. On the regulatory function of neuropeptide Y (NPY) with respect to vascular resistance and endocrine and exocrine secretion in the pig pancreas
61. Truncated glucagon-like peptide-1, an insulin-releasing hormone from the distal gut
62. Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum
63. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides
64. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
65. Response of plasma and tissue levels of enteroglucagon immunoreactivity to intestinal resection, lactation and hyperphagia
66. Distribution of glucagon-like peptide I (GLP-I), glucagon and glicentin in the rat brain: An immunocytochemical study
67. Immunohistochemical localization of glucagon-like peptide 1. Use of poly- and monoclonal antibodies
68. Gut GLI inhibits acid secretion in the rat
69. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung
70. Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exedin (9-39) amide
71. On the mechanism of the inhibition of gastric motility by fat. An inhibitory agent from the intestinal mucosa
72. Glucagon-like peptide-1 7-36: A physiological incretin in man
73. A role for GLP-1-(7-36)NH2 in the central control of feeding behaviour
74. Distribution of glucagon-like peptide-1 (GLP-1) and other preproglucagon derived peptides in the rat hypothalamusand brain stem
75. Glucagonlike peptide-1 (GLP-1) inhibits pancreatic enzyme secretion in humans
76. Ileal release of glucagon-like peptide-1 (GLP-1): Association with inhibition of gastric acid secretion in humans
77. The ileal brake: Ileal fat slows small bowel transit and gastric emptying in man
78. Effect of glucagon on gastric secretion in man
79. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36 amide), and peptide histidine methionine and is responsible for their degradation in human serum
80. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy
81. Pichlmayr. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after oesophageal resection
82. The pig as a model for human nutrition
83. Relationship of glicentin to proglucagon and the glucagon in the porcine pancreas
84. Regulation of gastric acid secretion by neurotensin in man: Evidence against a hormonal role
85. Preproglucagon gene expression in the pancreas and intestine diversifies at the level of post-translationel processing
86. Insulinotropin: Glucagon-like peptide-I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused pancreas
87. Vagal hepatopancreatic reflex evoked by intra portal appearance of tGLP-1
88. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects
89. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36 amide) infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal humans subjects
90. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinothropic effects in healthy humans
91. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
92. Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2-diabetic patients
93. Release of GLP-1 (7-36 amide) after oral glucose in patients with upper and lower gut resections
94. Identical mRNA for preglucagon in the gut and pancreas
95. Glucagon-like peptide-1 in the pathogenesis of obesity
96. Glucagonlike peptide-1 (7-36)-NH2: A physiological inhibitor of the gastric acid secretion in man
97. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer
98. Neurotensin inhibits meal-stimulated gastric acid secretion in man
99. Attenuated GLP-1 secretion in obesity: Cause or consequence?
100. Effect of infusion of nutrients into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon
101. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
102. Nutrient-independent increases in proglucagon and ornithine decarboxylase messenger RNAs after jejunoileal resection
103. Renal catabolism of truncated glucagon-like peptide-1
104. The effect of altered luminal nutrition on the cellular proliferation and plasma concentrations of enteroglucagon and gastrin after small bowel resection in rat
105. Glucagon-like peptide 1-a novel brain peptide involved in feeding regulation
106. Gastric emptying and release of incretin hormones after glucose ingestion in humans
107. Effects of GLP-1 on human antro-pylero-duodenal motility
108. GLP-1 (glucagon-like peptide-1) and the truncated GLP-1, fragment of the human proglucagon, inhibits gastric acid secretion in humans
109. Oxyntomodulin from the distal gut: Role in the regulation of gastric and pancreatic function
110. Rat parietal receptors for GLP-1 (7-36)amide. Northern blot, cross-linking and radioligand binding
111. Vagal cholinergic regulation of the secretion of pancreatic polypeptide
112. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
113. Relationship between molecular structures of the sugars and their ability to stimulate the release of Glucagon-like peptide-1 from canine ileal loops
114. Identification and localization of glucagon-like peptide 1 and its receptor in rat brain
115. Abdominal vagotomi blocks the satiety effect of cholecystokinin in the rat
116. The 'ileal brake' after ileal pouch-anal anastomosis
117. Passage of carbohydrates into the colon: Direct measurements in humans
118. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption
119. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats
120. Purification and chemical characterisation of the glicentin-related pancreatic peptide (proglucagon fragment) from porcine pancreas
121. The primary structure of glicentin (proglucagon)
122. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: Effect mediated through central or enteric nervous mechanisms
123. A role for glucagon-like peptide-1 in the regulation of feeding
124. Increased ileal proglucagon expression after jejunectomy is not suppressed by the inhibition of bowel growth
125. Distribution of glucagon-like peptide-1 in canine and feline pancreas and gastrointestinal tract
126. Localization of glucagon-like peptide-1 (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry
127. Tissue-specific expression of the human receptor for glucagon-like peptide-1: Brain, heart and pancreatic forms have the same deduced amino acid sequences
128. Pouchitis: Akut inflammation i det ileale bækkenreservoir
129. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effects on gastric acid secretion in man
130. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man
131. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): Non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans
132. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
133. Glucagon-like peptide-1 (GLP-1) inhibits antral motility and gastro-pancreatic secretion by inhibiting central parasympathetic outflow
134. The inhibitory effect of glucagon-like peptide-1 (7-36) amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide
135. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in man depends on an intact vagal innervation
136. Gastric emptying, glucose responses, and insulin secretion after liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
137. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs
138. Inhibition of human gastric lipase secretion by glucagon-like peptide-1
139. Glucagon-like peptide-1, a new hormone of the entero-insular axis
140. All products of proglucagon are elevated in plasma from uremic patients
141. Complete sequences of the glucagon-like peptide-1 (GLP-1) from human and pig small intestine
142. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the small intestine, but not pancreas
143. Effect of truncated glucagon-like peptide-1 (proglucagon-(78-107) .amide) on endocrine secretion from pig pancreas, antrum and nonantral stomach
144. Pancreatic and intestinal processing of proglucagon in man
145. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
146. GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1
147. Production and secretion of the amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man
148. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable
149. Secretion of the incretin hormones glucagon-like peptide-1 and the gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day